EMA Authorised: Simbrinza (brinzolamide;brimonidine tartrate) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Simbrinza, a fixed-dose combination of brinzolamide and brimonidine tartrate, for the treatment of ocular hypertension and open-angle glaucom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Open-angle
• Ocular Hypertension

Drugs mentioned

• Simbrinza (brinzolamide/brimonidine)

Snippet

Status: Authorised. Therapeutic area: Ocular Hypertension;Glaucoma, Open-Angle. MAH: Novartis Europharm Limited. Decision date: 22/01/2026